The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

Abstract Background Immune checkpoint inhibitors (ICIs) have become one important therapeutic strategy for advanced non‐small‐cell lung cancer (NSCLC). It remains imperative to identify reliable and convenient biomarkers to predict both the efficacy and toxicity of immunotherapy, and tumor‐associate...

Full description

Bibliographic Details
Main Authors: Jing Zhao, Yang Wu, Yuan Yue, Minjiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiaoyan Si, Wei Zhong, Xiaotong Zhang, Li Zhang, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitors
non‐small‐cell lung cancer
prognostic biomarker
tumor‐associated autoantibody
Online Access:https://doi.org/10.1111/1759-7714.14772

Internet

https://doi.org/10.1111/1759-7714.14772

Similar Items